The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve the use of erenumab as a treatment option for preventing migraine in line with NICE TA682.
Erenumab will be given a RED traffic light status for this indication
Erenumab is a payment by results drug and blueteq forms for initiation and continuation will be available for specialist teams to complete.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication
